Elisabeth Aloy and David Pistor, healthcare and life sciences advisors at Monitor Deloitte, outline five design principles to create a value-based care project.
Most healthcare systems are battling with the challenge of delivering both better patient outcomes – in an environment of increasing prevalence of diseases – while managing escalating costs. So how can we ensure the best possible care and access to innovation for patients, while being mindful of these costs and healthcare budget pressures?
In the past decade, the introduction of Health Technology Assessments (HTA), and the impact of austerity measures, have started to...
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
EFPIA says reforms make the continent less attractive for innovative firms.
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
